Published in Ther Adv Med Oncol on April 19, 2016
Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP) | NCT01746225
Triple negative breast cancer: the kiss of death. Oncotarget (2017) 0.78
Nonionic Microemulsions as Solubilizers of Hydrophobic Drugs: Solubilization of Paclitaxel. Materials (Basel) (2016) 0.75
Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial). ESMO Open (2017) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol (2005) 9.70
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol (2009) 5.64
Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol (2004) 4.51
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol (1998) 3.65
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol (2005) 3.62
The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer (2007) 2.84
Is breast cancer survival improving? Cancer (2004) 2.73
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res (2002) 2.66
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol (2005) 2.53
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol (2014) 2.45
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. Clin Pharmacokinet (2003) 2.44
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol (2009) 2.23
Extending survival with chemotherapy in metastatic breast cancer. Oncologist (2005) 2.17
Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst (2008) 2.15
Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol (2011) 2.10
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat (2006) 2.10
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res (1999) 2.06
Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs (2008) 2.01
Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol (2008) 1.88
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol (2016) 1.84
Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev (2014) 1.78
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol (2005) 1.70
Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer (2012) 1.67
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer (2007) 1.66
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol (2006) 1.65
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res (2007) 1.61
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol (2005) 1.54
Goals and objectives in the management of metastatic breast cancer. Oncologist (2003) 1.50
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res (2008) 1.48
Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids (2005) 1.46
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm (2010) 1.43
Management of triple negative breast cancer. Breast (2010) 1.43
Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer (2005) 1.37
Metastatic breast cancer: the treatment challenge. Clin Breast Cancer (2008) 1.22
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer (2010) 1.15
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat (2010) 1.14
Treatment of metastatic breast cancer: second line and beyond. Ann Oncol (2010) 1.10
A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clin Breast Cancer (2011) 1.09
Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer (2008) 1.03
Taxanes for the treatment of metastatic breast cancer. Breast Cancer (Auckl) (2012) 1.02
Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer (2013) 1.01
Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther (2007) 1.00
Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview. Curr Breast Cancer Rep (2013) 0.98
Goals of treatment for patients with metastatic breast cancer. Semin Oncol (2006) 0.96
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol (2014) 0.96
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol (2015) 0.94
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. Clin Breast Cancer (2013) 0.92
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat (2008) 0.91
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol (2011) 0.90
Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis. Breast (2011) 0.90
Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat (2013) 0.90
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen. Breast Cancer Res Treat (2012) 0.89
Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer (2003) 0.89
Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol (2014) 0.89
Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. Ther Adv Med Oncol (2013) 0.87
Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. Crit Rev Oncol Hematol (2012) 0.87
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Devel Ther (2015) 0.87
Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol (2010) 0.86
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity. Breast Cancer Res Treat (2012) 0.86
nab-Paclitaxel for the treatment of aggressive metastatic breast cancer. Clin Breast Cancer (2014) 0.85
Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective. Clin Breast Cancer (2015) 0.85
Nab-paclitaxel: a flattering facelift. Crit Rev Oncol Hematol (2014) 0.84
Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. Oncologist (2005) 0.83
Pharmacological factors influencing anticancer drug selection in the elderly. Drugs Aging (2003) 0.83
Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer. Expert Rev Anticancer Ther (2014) 0.82
Evaluation of the clinical benefits of nanoparticle albumin-bound paclitaxel in women with metastatic breast cancer in British Columbia. Curr Oncol (2013) 0.81
HER2-positive metastatic breast cancer: a changing scenario. Crit Rev Oncol Hematol (2015) 0.81
Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev (2003) 0.81
Late lines of treatment benefit survival in metastatic breast cancer in current practice? Breast (2011) 0.80
Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice. Anticancer Res (2013) 0.79
nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treat Rev (2014) 0.79
Treatment of metastatic breast cancer in women aged 65 years and older. Womens Health (Lond Engl) (2012) 0.79
Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre. Curr Oncol (2013) 0.78
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications. Expert Opin Drug Saf (2014) 0.78
Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. Drug Des Devel Ther (2015) 0.78
Older patients with breast cancer: is there bias in the treatment they receive? Ther Adv Med Oncol (2012) 0.78
Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age. Oncologist (2014) 0.77
Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007. Breast Cancer Res Treat (2006) 0.76
Medical treatment of elderly patients with breast cancer. Anticancer Agents Med Chem (2013) 0.76
Taxanes in the elderly: can we gain as much and be less toxic? Crit Rev Oncol Hematol (2008) 0.76
Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer. Anticancer Res (2014) 0.76